TECHNICAL TREND ( NIFTY - BANK NIFTY FUTURES ) NIFTY FIFTY : - Nifty futures and bank nifty future market closed at 10291/ 25365,.according to technical analysis if nifty futures and bank nifty future moves upward direction in upcoming treading sessions then 10400/ 24500 will be next resistance level, if it break this level then nifty futures and bank nifty future can touch 10500 / 26000 level . meanwhile in reveres there is support on 10200/25200 for nifty futures and bank nifty future after breaking this support with volume there is big support for nifty futures and bank nifty future on 10000/24800.
Monday, 11 Dec 2017
TECHNICAL VIEW (NIFTY- BANK NIFTY FUTURES )
NIFTY DAILY
WEEKLY
MONTHLY
R2
R1
PP
S1
S2
10528
10354
10266
10180
10006
R2
R1
PP
S1
S2
10950
10460
10215
9968
9478
R2
R1
PP
S1
S2
11510
107000
10295
9891
9081
R2
R1
PP
S1
S2
25800
25486
25328
25171
24856
BANK NIFTY DAILY
WEEKLY
MONTHLY
R2
R1
PP
S1
S2
26725
25718
25214
24709
23701
R2
R1
PP
S1
S2
28596
26583
25575
24569
22555
MOVING AVERAGE 21 DAYS
50 DAYS
100 DAYS 200 DAYS
NIFTY
10274
10240
10102
9738
BANK NIFTY
25528
25075
24794
23585
PARABOLIC SAR
DAILY WEEKLY MONTHLY
NIFTY
10494
9131
7674
BANK NIFTY
24801
21325
16225
PATTERN FORMATION ( NIFTY )
Details of Chart - Last week nifty opened at 10167and close at 10292 made high of 10298 and low of 10052,moved almost 240 point in upward direction. according to technical analysis if nifty can move further in upward direction then 10400 will be next resistance level of nifty if it can break this level then further can go in it lifetime high..
PATTERN FORMATION ( BANK NIFTY )
Detail of Chart - Last week banknifty opened at 25300 and close at 25365 made high of25390 and low of 24885 shows its consolidate movement acording to technical analysis if bank nifty can sustain the level of 25300 can show its upward movement can go upto 25600,next major resistance for bank nifty is 25600. if bank nifty can break this level can go upto 26000.
NSE EQUITY DAILY LEVELS COMPANY
R3
R2
R1
PP
S1
S2
S3
ADANIPORTS NAME AMBUJACEM ASIANPAINT
EQ EQ EQ
428.05 292.75 1238.35
408.50 279.00 1183.85
400.55 274.25 1159.70
388.95 265.25 1129.35
381.00 260.50 1105.20
369.40 251.50 1074.85
349.85 237.75 1020.35
AUROPHARMA AXISBANK BAJAJ-AUTO BAJFINANCE BHARTIARTL BOSCHLTD BPCL CIPLA COALINDIA DRREDDY EICHERMOT GAIL HCLTECH HDFC HDFCBANK HEROMOTOC HINDALCO O HINDPETRO HINDUNILVR IBULHSGFIN ICICIBANK INDUSINDBK INFRATEL INFY IOC ITC KOTAKBANK LT LUPIN M&M MARUTI NTPC ONGC POWERGRID RELIANCE SBIN SUNPHARMA TATAMOTORS TATASTEEL TCS TECHM ULTRACEMCO UPL VEDL WIPRO YESBANK ZEEL
EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ EQ
732.35 569.65 3476.90 1822.90 618.50 22331.00 559.55 636.65 289.35 2404.90 32283.45 578.10 952.10 1769.70 1943.85 3866.75 263.30 479.35 1476.35 1304.35 334.45 1747.70 420.10 1068.55 447.70 283.55 1043.95 1287.75 865.15 1503.25 10215.90 194.60 197.00 215.55 1000.90 338.05 560.70 444.05 795.85 2741.50 559.95 4485.75 820.85 325.70 305.75 339.35 616.80
700.35 554.35 3332.55 1759.95 564.50 21019.95 533.00 618.45 278.10 2309.25 30636.55 528.00 904.15 1720.55 1887.95 3705.10 250.55 449.35 1386.55 1246.35 320.70 1708.00 398.15 1030.10 422.90 271.20 1024.45 1249.75 842.40 1446.70 9546.95 187.05 188.60 208.45 959.40 326.15 541.00 425.30 742.70 2680.00 523.05 4304.35 768.70 306.90 295.25 324.45 591.10
686.70 548.90 3273.75 1732.95 544.15 20330.00 523.55 611.70 271.35 2247.85 29868.30 506.00 887.55 1701.95 1865.10 3613.55 244.40 438.70 1352.30 1225.70 315.75 1690.50 385.90 1014.75 414.20 266.85 1017.40 1234.50 833.05 1416.85 9305.95 184.30 185.00 205.85 940.35 319.70 532.50 418.10 718.40 2640.00 509.65 4229.55 748.45 298.55 288.90 318.50 577.60
668.35 539.05 3188.20 1697.00 510.50 19708.90 506.45 600.25 266.85 2213.60 28989.65 477.90 856.20 1671.40 1832.05 3543.45 237.80 419.35 1296.75 1188.35 306.95 1668.30 376.20 991.65 398.10 258.85 1004.95 1211.75 819.65 1390.15 8878.00 179.50 180.20 201.35 917.90 314.25 521.30 406.55 689.55 2618.50 486.15 4122.95 716.55 288.10 284.75 309.55 565.40
654.70 533.60 3129.40 1670.00 490.15 19018.95 497.00 593.50 260.10 2152.20 28221.40 455.90 839.60 1652.80 1809.20 3451.90 231.65 408.70 1262.50 1167.70 302.00 1650.80 363.95 976.30 389.40 254.50 997.90 1196.50 810.30 1360.30 8637.00 176.75 176.60 198.75 898.85 307.80 512.80 399.35 665.25 2578.50 472.75 4048.15 696.30 279.75 278.40 303.60 551.90
636.35 523.75 3043.85 1634.05 456.50 18397.85 479.90 582.05 255.60 2117.95 27342.75 427.80 808.25 1622.25 1776.15 3381.80 225.05 389.35 1206.95 1130.35 293.20 1628.60 354.25 953.20 373.30 246.50 985.45 1173.75 796.90 1333.60 8209.05 171.95 171.80 194.25 876.40 302.35 501.60 387.80 636.40 2557.00 449.25 3941.55 664.40 269.30 274.25 294.65 539.70
604.35 508.45 2899.50 1571.10 402.50 17086.80 453.35 563.85 244.35 2022.30 25695.85 377.70 760.30 1573.10 1720.25 3220.15 212.30 359.35 1117.15 1072.35 279.45 1588.90 332.30 914.75 348.50 234.15 965.95 1135.75 774.15 1277.05 7540.10 164.40 163.40 187.15 834.90 290.45 481.90 369.05 583.25 2495.50 412.35 3760.15 612.25 250.50 263.75 279.75 514.00
TOP 15 ACHIEVERS SR.NO
SCRIPT NAME
PREV CLOSE
// CMP
% CHANGE
TOP 15 LOOSERS SR.NO
SCRIPT NAME
PREV CLOSE
CMP
% CHANGE
1
BHARTI AIRTEL
484.30
533.15
+10.9
1
LAKVILA BANK
171.25
149.50
-12.70
2
MARUTI SUZUKI
8500.80
9118.95
+7.27
2
TEX MOPIPE PR
32.25
29
-10.36
3
TECH MAH LTD
472.80
497.45
+5.21
3
L&T TECH
1105.20
1005.05
-9.06
4
BHARAT PETRO
496.20
520.75
+4.95
4
APEX FRO FO
818.25
772.75
-5.56
5
HIND PETROL
412.40
431.30
+4.58
5
GITANJ GEMS
80.75
76.35
-5.45
6
ITC LTD
255.10
266.45
+4.45
6
RUPA & COM
479.05
453.95
-5.25
7
HINDU UNILEVER
1268.60
1323.50
+4.33
7
IRB INFRA
213.65
203.60
-4.70
8
INDIA OIL CORPO.
390.55
406.45
+4.07
8
JUBIL FO WORK
1732.30
1676.05
-3.25
9
GAIL( INDIA ) LTD
463.15
479.35
+3.50
9
FO HEALTCARE
148.35
143.55
-3.24
10
AMBUJA CEMENT
261.10
270.25
+3.50
10
JINDAL STL
106.90
103.50
-3.18
11
HCL TECHNOLOGI
847.95
876
+3.31
11
NITCO LTD
109.55
106.10
-3.15
12
YES BANK
303.20
312.75
+3.15
12
JINDAL & PWR
169.25
164
-3.10
13
UPL
711.05
732
+2.95
13
HCL INF SYS
52.25
50.65
-3.06
14
LUPIN LTD
814.45
836.80
+2.74
14
HINDZINC
299.70
292.40
-2.44
15
ULTRA TECH CEM
4110.05
4220.05
+2.68
15
HEROMOTOCO
3601.40
3522.35
-2.19
AM 204 BUJ A CEM ENT
232
+13.67 %
AMBUJA CEMENT
NEXT WEEK STARS (AS PER TECHNICAL ANALYSIS) NSE FUTURE
NSE FUTURE : BUY INDUSIND BANK FUTURE ABOVE 1700 TGT 1750 SL 1680 NSE FUTURE : SELL GAIL FUTURE BELOW 480 TGT 475 SL 484
NSE CASH
NSE CASH : BUY AUBANBK CASH ABOVE 720 TGT 760 SL 700 NSE CASH : BUY MUTHOOT FINANCE IN NSE CASH ABOVE 447 TGT 492 SL 430
NSE - WEEKLY NEWS LETTERS ✍ TOP NEWS OF THE WEEK
Next week once again promises to be full of action as a slew of macro-economic data are scheduled to be announced.The October Industrial production data will be released on December 12 and December 14 will see the Wholesale price inflation data for the month of November released.Apart from domestic data all eyes will also be on the FED interest rate decision.
Upcoming events DEC 12 – OCT IIP YOY DEC 13 – FED INTEREST RATE DECISION DEC 14 – NOV WPI INFLATION YOY
RBI KEEPS THE REPO RATE UNCHANGED AT 6% -
On the basis of an assessment
by Monetary Policy Committee decided to keep the policy repo rate under the liquidity adjustment facility unchanged at 6%.Consequently, the reverse repo rate under the LAF remains at 5.75%, and the marginal standing facility rate and the Bank Rate at 6.25%.The decision of the MPC is consistent with a neutral stance of monetary policy in consonance with the objective of achieving the medium-term target for consumer price index inflation of 4% within a band of +/- 2% while supporting growth.The decision was executed with a majority vote of 5 out of 6 in favor of the monetary policy decision.
RBI'S NEUTRAL STANCE IN CONSONANCE WITH INFLATION TARGET OF 4% -
MEDIUM-TERM CPI
On the basis of an assessment of the current and
evolving macroeconomic situation the Monetary Policy Committee decided to keep the policy repo rate under the liquidity adjustment facility unchanged at 6.0%. The decision of the MPC is consistent with a neutral stance of monetary policy in consonance with the objective of achieving the medium-term target for consumer price index inflation of 4%.The headline inflation outcomes have evolved broadly in line with projections. RBI mentioned that going forward, inflation should be influenced by several factors:
The moderation in inflation excluding the food and fuel observed in Q1FY17-18 has by and arge reversed and there the upward trajectory may continue; Impact of HRA by the central government is expected to peak in December and the staggered impact of increase in HRA by various state government may further push up the housing inflation;
The recent rise in international crude oil prices may sustain and in such a scenario, any adverse supply shock due to geopolitical developments could push up prices even further.
In addition to the above some seasonal moderation in vegetable prices is expected in the near term. Also, the GST council in its last meeting has brought several retail goods and services to lower tax brackets, which should translate into lower retail prices, going forward.
BHEL BAGS RS215CR R&M ORDER FROM BIHAR POWER PLANT - Bharat Heavy Electricals Limited has secured an order for Electrostatic Precipitators at NTPC's Kahalgaon Super Thermal Power Station in Bihar. The turnkey order includes carrying out R&M of the ESPs originally supplied by BHEL. These ESPs have been operating successfully for more than 25 years since the commissioning of the plant. BHEL's scope of work in the contract includes design, engineering, manufacture, supply, dismantling, erection, testing and commissioning of the ESPs to bring down the suspended particulate matter emission to the recommended level for all the four units of this STPS.
With this order, BHEL has consolidated itself as the market leader in ESPs. BHEL is already executing similar R&M projects for NTPC and state utilities like GSECL, CSPGCL, etc. BHEL’s order book at the end of September 2017 stood at Rs97,000cr , while order inflows came in at Rs1,870cr in Q2FY18. The stock trades at~22xFY19E EPS. As per media reports, BHEL is also well placed on Rs5,000cr, 800 MW EPC order from Singaneri Collieries, Telangana.
TVS MOTOR ACQUIRES 15% STAKE IN ELECTRIC TWO-WHEELER STARTUP ULTRAVIOLETTE FOR RS.5CR - TVS Motor bought 14.78% stake in Ultraviolette Automotive Pvt. Ltd, a Bengaluru-based startup working on electric two-wheelers and energy infrastructure, for Rs5cr. Ultraviolette Automotive was incorporated in December 2015 and has reported Rs3.2lakh revenue for FY17. It has tested three prototypes, however, has not launched an electric two-wheeler yet. Additionally, TVS is developing an electric scooter code-named U218 in order to compete in the category with players like Bajaj Auto Ltd, Honda Motorcycle and Scooter India Pvt. Ltd, Mahindra 2 Wheelers Ltd and India Yamaha Motor Pvt. Ltd, which are all set to launch electric two-wheelers in 2018, as per the media reports. This acquisition would provide the expertise exposure in the electric two-wheeler segment.
DEEPAK NITRITE PLANS TO RAISE FUNDS VIA QIP - Deepak Nitrite is planning to raise funds through Qualified Institutions Placement of equity shares of the company. The meeting of Board of Directors of the company is scheduled to be held on December 11, 2017, to consider the same. This fundraising is to finance its capex plans for its high margin projects, which would improve its revenues and margins going ahead. The company had already raised Rs150cr via a Qualified Institutional Placement in March 2017. Out of the net proceeds, the company has invested Rs 64 cr towards the phenol project. DNL is well-positioned to drive strong earnings growth in quarters to come, driven by 1) Commissioning of the phenol-acetone plant 2) Volume growth and margin expansion in fine and specialty chemicals 3) Turnaround in the performance products segment 4) Tailwinds for the basic chemicals segment from stricter environmental norms in China.
DELHI GOVERNMENT CANCELS LICENSE OF MAX HOSPITAL’S SHALIMAR BAGH - Max India Ltd’ equal joint venture with Life Healthcare, Max Healthcare Institute Ltd has received a notice of cancellation of the license of one of its hospitals at Shalimar Bagh, New Delhi from Government of NCT of India. The license cancellation order was imposed after a premature baby was wrongly declared dead last week. A panel formed by the Delhi government to look into the case found the hospital administration guilty of not following prescribed medical norms in dealing with newborn infants. Max Healthcare Institute Ltd, through its press release, has expressed that the ruling is harsh and no adequate opportunity to be heard has been given by the government. The company also mentioned in the press release that “even if there is an individual error of judgement, holding the hospital responsible is unfair and will severely limit the ability for patients to access treatment. This will compound the shortage of hospital facilities in the National Capital”.
IRB INFRA DOWN 3.9% AFTER CBI FILES CHARGESHEET - IRB
Infrastructure
Developers Ltd disclosed that its subsidiary Aryan Infrastructure Investments Private Limited along with certain other persons have been charge-sheeted by the CBI in the matter of an illegal purchase of government land. AIIPL had begun purchasing land parcels in 2007 and eventually acquired 1200 acres of land. In early 2009, AIIPL observed that ~5% of the land was owned by the Maharashtra State Road Development Corporation. After this observation, AIIPL canceled the land sale agreements for these land parcels. The company believes that this development should not have a material impact on the business or operations of the company. GAIL AWARDS CONTRACT FOR LAYING 520KM PIPELINE NETWORK - GAIL India announced that it had awarded contracts for a 520-km pipeline under the Pradhan Mantri Urja Ganga gas pipeline project. With the awarding of these major contracts, phase-II of the Jagdishpur-Haldia and Bokaro-Dhamra Natural Gas Pipeline project has been finalised. The 2,655-km long JHBDPL project, also known as the 'Pradhan Mantri Urja Ganga' project, will pass through Uttar Pradesh, Bihar, Jharkhand, West Bengal and Odisha. The project will cater to the demands of industrial users like fertilizer plants, power generation plants, refineries, steel plants and other power intensive industries.
GAIL also stated that city gas network laying activity in Varanasi and Bhubaneswar has already begun. Laying of city gas network will begin in Patna, Ranchi, Jamshedpur, Cuttack and Kolkata by next month. GAIL announced a capex commitment of Rs6,000cr for FY18, an increase of 50% from last year’s capex. These are long term positive developments for the stock and should have a positive effect on the price. GAIL’s revenue from various segments for FY17 stood at 71% gas marketing, 10% gas transmission and 19% from others. NEW INDIA ASSURANCE BAGS RAJASTHAN HEALTH INSURANCE PROJECTNew India Assurance Company Limited has announced that it will execute health insurance for about one crore poor families across the State. Under the project called the Bhamasha Swasthya Bima Yojana, about four crore people covered under the National Food Security Act will get health insurance benefits. This is one of the largest health insurance schemes in the country, as it gives cover for cashless treatment of 1,401 diseases - of Rs 3,00,000 for 663 critical and Rs 30,000 each for 738 general illnesses. G Srinivasan, Chairman and MD, NIA said, “This is one of the unique universal health insurance schemes in the country and the scheme is operated through a large number of empanelled hospitals both public and private .“ The total insurance premium involved is more than Rs1,200cr per annum with the State bearing Rs1,261 per family. The basic aims of the Bhamashah Swasthya Bima Yojana is improvement in health indicators, reduction in out of pocket expenses and providing financial security to the poor against illnesses, to roll out Government’s vision of maximum Governance and minimum Government and bring a revolution in healthcare in rural area – by providing stimulus to Private Sector to open hospitals in rural areas and reducing the increasing burden on Government facilities. NIA is the largest general insurance company in India in terms of net worth, domestic gross direct premium, profit after tax and number of branches. The company has been in operation for almost a century. NIA has the largest market share of gross direct premium among general insurers in India NIA’s operations are spread across 29 States and seven Union Territories in India and across 28 other countries globally through a number of international branches, agency offices and subsidiaries including a desk at Lloyd’s, London.
The Gross Written Premium for the half year ended September 30, 2017, was Rs12,823.49cr as against a figure of Rs11,203.62cr in the previous year, registering a growth of 14.46%. The Return on Equity of the company for the first half was 19.98% as compared to 8.52% during the same period the previous year. The Solvency margin as on September 30, 2017 was very comfortable at 2.24x as compared to 2.04x of the earlier year.
CADILA HEALTHCARE’S ARM RECEIVES FINAL APPROVAL FROM USFDA FOR CLOZAPINE TABLETS - Cadila Healthcare’s wholly owned subsidiary - Zydus Pharmaceuticals Inc., has received the final approval from the US Food and Drug Administration to market Clozapine Tablets in strengths of 25 mg, 50 mg, 100 mg, and 200 mg. The drug is used to treat schizophrenia. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. The stock to react positively on this news, as it will consolidate Cadila’s position in the US generic market and improve its US Sales.The company now has more than 175 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04. SHAREHOLDERS OF AXIS BANK APPROVE THE BOARD’S CAPITAL RAISING PLAN OF RS11,626CR - The shareholders of Axis Bank Ltd approved capital raising plan proposed by the board on December 8, 2017.The proposal by the board of directors of the bank was to raise equity and equity-linked capital of Rs11,626cr from a set of marquee investors including entities affiliated with Bain Capital Private Equity, other investors advised by Capital Research and the bank’s promoter, Life Insurance Corporation of India.The bank has received approval for the capital raising plan from the board of directors on November 10, 2017.Axis Bank is the third largest private bank in India in terms of the loan book. It retains a strong market position in corporate lending due to its superior banking channels and debt capital service capabilities.It’s loan mix as on FY17 consisted of corporate, retail segment and SMEs, contributing 45%, 42%, and 13% respectively. Also, its FY17 GNPA's and NNPA's stood at 5.5% and 2.3% respectively.
ULTRATECH TO SETUP 3.5 MTPA INTEGRATED UNIT IN PALI, RAJASTHAN UltraTech Cement has approved the setting up of a 3.5 MTPA integrated unit at Pali, Rajasthan. The plant is expected to get commissioned by June 2020 with a total capital expenditure of Rs1,850cr. This move has come up in order to cater to the western Rajasthan where the company does not have a significant presence. In addition, the board of UltraTech also approved the increase in the investment limit by Registered Foreign Portfolio Investors, including FII, from the existing limit of 30% of the paid-up equity share capital of the company to 40%, subject to shareholders approval UCL is the largest pan India cement company with a capacity of 89 MTPA. UCL enjoys a premium position in the most markets it operates. UCL’s cement capacity increased from 22 MTPA to 49 MTPA in July 2010 following a merger with standalone cement business of Grasim Industries. In FY18, UCL’s capacity further increased by ~25% through the acquisition of 21.2mtpa capacity of JPA. In addition, the company has 80% stake in Dubai based Star Cement, 0.5 MTPA cement grinding capacity in Bangladesh, and 0.4mtpa cement grinding capacity in Bahrain. In the last trading session. GLENMARK PHARMA ANNOUNCES DOSING OF FIRST PATIENT WITH INVESTIGATIONAL IMMUNO-ONCOLOGY AGENT -
Glenmark
Pharmaceuticals
announced that the first patient has been dosed in a Phase 1 trial of GBR 1342 (NCT03309111), an investigational bispecific antibody. This first-in-human, open-label study’s primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached. This trial is a step in a right direction as it will strengthen its higher-margin biologics pipeline with lesser competition. Three of the company’s biologics, two of which are immuno-oncology agents, have begun clinical trials. Glenmark’s immuno-oncology pipeline currently includes three candidates being studied in a wide range of tumor types. It has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of immuno-oncology, respiratory disease and dermatology. The company is also pursuing partnership opportunities for four of its novel molecules & expects to out-license at least one of them in FY18E. This may help in debt reduction.
LEGAL DISCLAIMER
This Document has been prepared by Ways2Capital (A Division of High Brow Market Research Investment Advisor Pvt Ltd). The information, analysis and estimates contained herein are based on Ways2Capital Equity/Commodities Research assessment and have been obtained from sources believed to be reliable. This document is meant for the use of the intended recipient only.
This document, at best, represents Ways2Capital Equity/Commodities Research opinion and is meant for general information only. Ways2Capital Equity/Commodities Research, its directors, officers or employees shall not in any way to be responsible for the contents stated herein. Ways2Capital Equity/Commodities Research expressly disclaims any and all liabilities that may arise from information, errors or omissions in this connection. This document is not to be considered as an offer to sell or a solicitation to buy any securities or commodities.
All information, levels & recommendations provided above are given on the basis of technical & fundamental research done by the panel of expert of Ways2Capital but we do not accept any liability for errors of opinion. People surfing through the website have right to opt the product services of their own choices.
Any investment in commodity market bears risk, company will not be liable for any loss done on these recommendations. These levels do not necessarily indicate future price moment. Company holds the right to alter the information without any further notice. Any browsing through website means acceptance of disclaimer.
DISCLOSURE High Brow Market Research Investment Advisor Pvt. Ltd. or its associates does not do business with companies covered in research report nor is associated in any manner with any issuer of products/ securities, this ensures that there is no actual or potential conflicts of interest. To ensure compliance with the regulatory body, we have resolved that the company and all its representatives will not make any trades in the market. Clients are advised to consider information provided in the report as opinion only & make investment decision of their own. Clients are also advised to read & understand terms & conditions of services published on website. No litigations have been filed against the company since the incorporation of the company.
Disclosure Appendix: The reports are prepared by analysts who are employed by High Brow Market Research Investment Advisor Pvt. Ltd. All the views expressed in this report herein accurately reflects personal views about the subject company or companies & their securities and no part of compensation was, is or will be directly or indirectly related to the specific recommendations or views contained in this research report.
Disclosure in terms of Conflict of Interest: (a) High Brow Market Research Pvt. Ltd. or his associate or his relative has no financial interest in the subject company and the nature of such financial interest; (b) High Brow Market Research Pvt. Ltd. or its associates or relatives, have no actual/beneficial ownership of one percent or more in the securities of the subject company, (c) High Brow Market Research Pvt. Ltd. or its associate has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
Disclosure in terms of Compensation: High Brow Market Research Investment Advisor Pvt. Ltd. policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst's area of coverage. Analyst compensation: Analysts are salary based permanent employees of High Brow Market Research Pvt. Ltd.
Disclosure in terms of Public Appearance: (a) High Brow Market Research Pvt. Ltd. or its associates have not received any compensation from the subject company in the past twelve months; (b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report. (c) High Brow Market Research Pvt. Ltd. or its associates has never served as an officer, director or employee of the subject company; (d) High Brow Market Research Pvt. Ltd. has never been engaged in market making activity for the subject company.